SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte fusion
Jay Schneider,David Pease,Chanakha Navaratnarajah,Peter Halfmann,Daniel Clemens,Dan Ye,Changsung Kim,Alison Barkhymer,Stephen Cohle,Aron Banks,Arpit Mehta,Joseph Rantus,Tim Emmerzaal,Tamas Kozicz,Kyle Howell,Jon Charlesworth,Trace Christensen,Yoshihiro Kawaoka,Leslie Cooper,Michael Ackerman,Roberto Cattaneo
DOI: https://doi.org/10.21203/rs.3.rs-95587/v1
2020-01-01
Abstract:Abstract Viruses spread between hosts through particles, but within hosts, viral genomes can spread from cell to cell through fusion, evading antiviral defenses and obviating costly infectious virion production1-3. Billions of electromechanically coupled cardiomyocytes (CMs) make myocardium inherently vulnerable to pathological electromechanical short circuits caused by intercellular viral spread 4-6. Beyond respiratory illness, COVID-19 affects the heart7 and cardiac injury and arrhythmias are serious public health concerns8-12. By studying myocardium of a young woman who died suddenly, diagnosed postmortem with COVID-19, we discovered highly focal myocardial SARS-CoV-2 infection spreading from one CM to another through intercellular junctions identified by highly concentrated sarcolemmal t-tubule viral spike glycoprotein. SARS-CoV-2 permissively infected beating human induced pluripotent stem cell (hiPSC)-CMs building multinucleated cardiomyotubes (CMTs) through cell type-specific fusion driven by proteolytically-activated spike glycoprotein. Recombinant spike glycoprotein, co-localizing to sarcolemma and sarcoplasmic reticulum, produced multinucleated CMTs with pathological structure, electrophysiology and Ca2+ excitation-contraction coupling. Blocking cleavage, a peptide-based protease inhibitor neutralized SARS-CoV-2 spike glycoprotein pathogenicity. We conclude that SARS-CoV-2 spike glycoprotein, efficiently primed, activated and strategically poised during biosynthesis, can exploit the CM’s inherent membranous connectivities to drive heart damage directly, uncoupling clinically common myocardial injury from lymphocytic myocarditis, often suspected but rarely confirmed in COVID-19.